Skip to main content
. 2022 Feb 18;37(2):238–247. doi: 10.1016/j.virs.2022.02.005

Fig. 1.

Fig. 1

Evaluation of the biodistribution of F61 monoclonal antibodies in mice. A Representative whole-body images. B–D Quantification of fluorescence signals in mice after intranasal delivery of different doses and at different time points (B: 24 ​h, 10 ​mg/kg; C: 48 ​h, 5 ​mg/kg; D: 48 ​h, 1.25 ​mg/kg). E–J Representative ex vivo images. 24 ​h, 10 ​mg/kg (E, H); 48 ​h, 5 ​mg/kg (I, F); 48 ​h, 1.25 ​mg/kg (G, J). K–N Quantification of the average radiant efficiency of different organs at different time points (K: 2 ​h, L: 24 ​h, M: 48 ​h, N: 96 ​h) after nasal delivery of F61 (1.25 ​mg/kg). O–REx vivo imaging of different organs at different time points (O: 2 ​h, P: 24 ​h, Q: 48 ​h, R: 96 ​h) after nasal delivery of F61 (1.25 ​mg/kg). Br, brain; H, heart; K, kidney; Lu, lung; Lv, liver; NC, nasal cavity; S, spleen; J, jejunum; U, urocyst. Data are means ​± ​standard deviations in four mice, as determined by Student's t-test. Dashed line: average autofluorescence of organs.